A coalition of US companies, workers, trade associations, opinion leaders and policy makers committed to building job-generating global free-trade partnerships.
TAPP Joins 50+ Organizations on Coalition Letter to State Lawmakers Articulating Principles for American Energy Abundance
Read about it here:
https://t.co/TPmdyrV37i
TAPP Encourages Senate Judiciary: Focus on Real Obstacles to Drug Affordability in Upcoming Hearing
American patients deserve affordable medicines, transparent pricing, and meaningful competition.
Read our letter to the committee here:
https://t.co/bWo6ezQHgD
Coalition Including TAPP Warns Against Codifying Gov’t Ownership of Equity Stakes in Private Corporations
"...continued federal investment in private companies is deeply troubling and sets a dangerous precedent..."
Read more:
https://t.co/PuidtDCPBC
@RSI
TAPP Signs onto Coalition Letter to Congress w/30+ Orgs in Support of Permitting Reform Bill that includes:
-Smarter environmental review
-Firm timelines
-Faster related reviews
-Litigation reform
-Limits on single-state veto
-Permit certainty
Read more:
https://t.co/RdqOytKyEh
TAPP Signs onto Coalition Letter to OMB on Definition of Ultra-Processed Foods
The administration should commit to protecting American families from higher grocery costs, advancing the health & well-being the MAHA agenda was meant to deliver.
Read more:
https://t.co/zaNgQIWBu9
NEW: @MFPatient scorecard reveals which countries have answered @POTUS' call to end foreign freeloading on American innovation.
Through trade negotiations, the US has made a deal with the UK to put patients first. Germany, Japan, and France have not yet done so.
See the full scorecard: https://t.co/oQmCke8PAT
A scientific discovery means nothing to patients if it never becomes a treatment.
As China expands its footprint in biopharmaceutical innovation, America’s ability to transform promising research into lifesaving medicines is more important than ever.
Strong IP protections empower innovators to bring new treatments to market–ensuring that innovative breakthroughs remain within reach for American patients. https://t.co/DiSlWrN3W4
CASM Executive Director @Andrew_Langer sat down with @Council4IP’s Andrei Iancu, former Director of @USPTO, to discuss the critical role of strong IP protections in driving medical innovation.
As China attempts to close the gap in biopharmaceutical innovation, America cannot afford to weaken the incentives that make the development of groundbreaking new treatments possible.
Listen to their conversation on @TheLunchHourPod about the role of patents, private investment, and innovation in securing America's competitive edge: https://t.co/wlwV0W3R4z
MEDICARE FOR ALL MEANS MEDICARE FOR NO ONE.
With Medicare’s Hospital Insurance Trust Fund projected to be depleted by 2033, proposals to expand an already strained program raise concerns about sustainability.
@StephenMoore warns government-run healthcare restricts access to treatments and provides patients with more barriers to care. https://t.co/wMkY06PgD2
TAPP Urges Treasury: Don’t Let COINS Act Hinder American Medical Leadership
COINS Act regulations restrict licensing agreements, acquisitions, & co-development partnerships essential to American drug innovation--a serious mistake.
Read more: https://t.co/SdNlTtxzwI
This National IP Month, Let’s Make the Patent System Work for Inventors
We should celebrate American ingenuity by strengthening the institutions that protect it.
Read more:
https://t.co/IaCpLlV5yC
#IP#intellectualproperty
National IP Month: Protecting American Innovation and America’s Competitive Edge
America has long prospered because people with bold ideas have had the freedom and incentives to pursue them.
Read our blog:
https://t.co/fWfl1hyoIY
National IP Month: Congress Must Protect the Patents That Power Medical Innovation
Efforts to undermine patents in the name of lowering healthcare costs risk producing the opposite long-term result: reducing incentives to invest in new medicines.
More: https://t.co/tYxM5yfp7G
TAPP Disappointed with CMS Finalization of GLOBE Model
The administration should use America’s considerable economic & trade leverage to demand wealthy trading partners contribute more fairly to the cost of developing innovative medicines.
Read more: https://t.co/jQDOufL916
An excellent column in @InsideSourcesDC Journal today by Ray Haynes: "Employers Are Voting With Their Feet on PBMs"
"Policymakers can learn a lesson here: Competition and transparency can accomplish what government price controls cannot."
Full op-ed:
https://t.co/ihhAXsn4Go
IRA “negotiations”—price controls in disguise—have some serious baggage.
By distorting the free market, government price-setting threatens investment in new treatments while limiting patient access to critical medicines.
Actually lowering costs means promoting competition and innovation. @TheHill
https://t.co/aChKTaoz0o